Table 1. Baseline characteristics of participants (n=135) included in post-hoc analysis.
| Characteristics | Bamlanivimab (4200 mg) | Placebo | ||
| Residents N=22 |
Staff N=51 |
Residents N=14 |
Staff N=48 |
|
| Age, Median (range) |
63 (31 - 95) |
43 (20 - 74) |
82 (63 - 93) |
44 (19 - 67) |
| Sex, No. (%) Male Female |
10 (45%) 12 (55%) |
11 (22%) 40 (78%) |
5(36%) 9 (64%) |
4 (8%) 44 (92%) |
| High-risk of severe COVID-19, No. (%) |
22 (100%) |
24 (47%) |
14 (100%) |
21 (44%) |
| Vaccine, No. (%) SpikeVax Comirnaty |
8 (36%) 14 (64%) |
10 (20%) 41 (80%) |
7 (50%) 7 (50%) |
14 (29%) 34 (71%) |
High-risk categorization criteria ( 13 )